La cadena de opciones muestra datos clave de las opciones de acciones de Oryzon Genomics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Oryzon Genomics..

Oryzon Genomics (OTC:ORYZF) Bolsa, Cadena de Opciones

Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.

Oryzon Genomics SA

News

Contracts

LUNR

Texas Space Commission Selects Intuitive Machines For Up To $10M Grant From Space Exploration and Research Fund

As the U.S. and China continue to send mixed signals about the progress of their trade talks, economists at&nbsp;Morgan Stanley&nbsp;project that both nations will begin negotiations and slowly decrease&nbsp;tariffs on Chinese imports to&nbsp;60% by the end of Q2.
What Happened: Despite the anticipated discussions, tariffs are not expected to revert to their pre-January 25 levels. More in-depth talks in the second half of the year could further lower tariffs on Chinese imports to 34% by the end of 2025, indicating the abolition of the 20% fentanyl-related tariff.
"We believe that both the US and China will want a comprehensive deal, but that given the multiple issues involved, the discussions are likely to be complex and will take time to complete," stated Morgan Stanley, <a href="https://www.scmp.com/economy/global-economy/article/3308345/us-china-seen-reducing-tariffs-year-much-damage-already-done-analysts-say?module=top_story&amp;pgtype=homepage">reported</a> The SCMP.
Due to the ongoing disruption in the economic cycle, Morgan Stanley anticipates that growth will continue to decline. The firm warned in its note, &#8220;Unless tariff-related uncertainty is resolved quickly, the path ahead could be towards a sharp, synchronous slowdown.&#8221;
China&#8217;s economic growth in the second quarter is currently projected to fall below 4.5%, a slowdown from the 5.4% expansion recorded in the first quarter, according to Robin Xing, Morgan Stanley&#8217;s chief China economist.
Although China is anticipated to introduce another stimulus package of &nbsp;1-1.5 trillion yuan (nearly $137.5 billion) in the latter half of the year, Morgan Stanley cautions that it will fall short of fully countering the growth shock caused by tariffs.
Meanwhile, Nomura cautioned if China were to lose 50% of its exports to the U.S., it could face a direct GDP reduction of approximately 1.1% in the short term.
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/04/45057119/anthony-scaramucci-bought-1200-worth-of-microsoft-stock-for-his-son-in-1992-and-then-forgot-about-it-three-decade" target="_blank" rel="noreferrer noopener">Anthony Scaramucci Once Purchased $1,200 Worth Of Microsoft Stock For His Son In 1992 And Then Forgot About It — Three Decades Later, It Quietly Turned Into A Small Fortune That He Didn&#8217;t Know He Ow</a>
Why It Matters: To date, Washington has implemented tariffs amounting to 145% on Chinese imports, pushing the overall effective tariff rate to around 156%. In retaliation, Beijing has increased its tariffs on U.S. goods to 125%, adding to earlier duties already in place.
The ongoing tariff war has had significant repercussions on various sectors. For instance,&nbsp;<a href="https://www.benzinga.com/25/04/45059743/china-open-to-co-operate-with-us-firms-voices-concern-over-trade-war-impact-as-tariffs-hits-chinese-airlines-and-boeing">Chinese airlines and Boeing</a>&nbsp;have been adversely affected by U.S.-imposed tariffs. Despite this, there are differing opinions on the potential economic impact. 
CNBC&#8217;s Jim Cramer&nbsp;<a href="https://www.benzinga.com/markets/equities/25/04/45058829/jim-cramer-dismisses-recession-panic-says-tariffs-may-sting-but-too-many-jobs-for-economy-to-derail">dismisses recession fears</a>, arguing that strong employment trends could prevent an economic downturn. However,&nbsp;<a href="https://www.benzinga.com/news/25/04/44913962/donald-trumps-trade-war-jpmorgan-predicts-deals-higher-taxes-and-potential-recession-avoidance">JPMorgan</a>&nbsp;has predicted that the tariff war could lead to agreements between the U.S, and its trade partners, along with a significant rise in tax rates.
Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) declined 7.4%, while the&nbsp;SPDR S&amp;P 500&nbsp;ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) lost 5.78% on a year-to-date basis, amid tariff uncertainties.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/general/sports/25/04/45027895/why-shaq-wont-share-his-500-million-fortune-with-his-kids-we-aint-rich-im-rich-im-not-going-to-hand-it-to-you-you-gotta-earn-it" target="_blank" rel="noreferrer noopener">Why Shaq Won't Share His $500 Million Fortune With His Kids: ‘We Ain't Rich. I'm Rich. I'm Not Going to Hand It to You, You Gotta Earn It&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

US, China To Ease Tariffs Gradually After 'Complex' Talks, Says Morgan Stanley — But Cuts China's Growth Outlook

Approximately $1.7 million in product orders are expected to be recognized in fiscal 2026

ALOT

AstroNova Wins $10M Multi-Year Defense Industry Contract

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistically different FDA approved anticancer first line therapies both in vitro and in vivo
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that an abstract and poster presentation regarding the Company's next-generation anthracycline, <a href="https://www.globenewswire.com/Tracker?data=zMBqbidS4LQA1S7fbn3PZhXfXzcxSvzhdfQuHUVO-SsFA0PD6bJcUHZORfhgpqRe8EY9wADIXFyqcTM8Qwgz7JLveCs_xMDixJ2BLQBWCpI=">Annamycin</a>, was presented at the <a href="https://www.globenewswire.com/Tracker?data=qQb184I71tqjyRhQ-GjKdptMM-tMvyWkWLtH9kQJaRkS7iRzdL9JHY8KSqkKh_ffpwFkr7X43SoS-zr5uOnoINb9kRqlIWvQvcpWK-kVeaKL7I6vQq-aqXTCoIBKiQx5UVIKi44s0nKo0BpQparUnF5AyJhjHy0qTftsO78LSuK7rn1ih4QQzcSKnNYOn0eiSV_WzgsTpwrOOShzfF4rQg==">American Association for Cancer Research (AACR) Annual Meeting 2025</a>, on April 28, 2025, at the McCormick Place Convention Center in Chicago, IL.

MBRX

Moleculin Presents New Pre-Clinical Data For Annamycin Demonstrating Market Expansion Potential Including Treatment For Pancreatic Cancer At AACR 2025

Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) with a Buy and lowers the price target from $3.5 to $2.5.

Price Target

Analyst Ratings

BDSX

Canaccord Genuity Maintains Buy on Biodesix, Lowers Price Target to $2.5

Baird analyst Joe Vruwink maintains Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) with a Outperform and raises the price target from $293 to $325.

CDNS

Baird Maintains Outperform on Cadence Design Systems, Raises Price Target to $325

Worksport Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) ("Worksport" or the "Company"), a U.S. based manufacturer and innovator of hybrid and clean energy solutions for the light truck, overlanding, and global consumer goods sectors, is pleased to announce a major expansion of its business-to-business (B2B) network. The Company has partnered with Patriot Automotive Technologies, a leader in automotive aftermarket accessories and customizations. This strategic relationship will see Worksport's innovative line of tonneau covers, sold through Patriot's network of over 200 dealer locations nationwide.

WKSP

Worksport Partners With Patriot Automotive Technologies To Accelerate Nationwide Expansion And Drive Millions in Annual Recurring Revenue

WIIM

ITRM

Iterum Therapeutics shares are trading lower after the company announced a $5 million registered direct offering.

"Alcoa's San Ciprián complex was impacted by the widespread power outage across Spain. As a result of the outage, both the refinery and smelter at the complex were affected. The Company is conducting a thorough assessment of the facility to determine the full extent of the operational and financial impact."

Alcoa Issues Statement Following Power Outage In Spain

ASNS

Actelis Networks Receives Infrastructure Modernization Order In Japan, Terms Not Disclosed

LFMD

LifeMD shares are trading higher after the company announced it will offer access to Wegovy.

Nuvve Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) on Tuesday announced the acquisition of Fermata Energy LLC, a V2G platform provider in the U.S.
The acquisition was completed through Nuvve&#8217;s newly formed subsidiary, Fermata II LLC (Fermata 2.0), which focused on scaling intelligent, bidirectional energy solutions.
Fermata 2.0 issued 4,900,000 shares of convertible preferred stock to former Fermata debt holders as part of the transaction. The total purchase price is approximately $659,000, consisting of $340,000 in cash and the remainder in assumed liabilities.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/04/44959619/exclusive-defi-development-adds-9-9-million-in-solana-tokens-underscoring-its-commitment-towards-digital-asset-treasury-strategy" rel="noreferrer noopener">EXCLUSIVE: DeFi Development Adds $9.9 Million In Solana Tokens Underscoring Its Commitment Towards Digital Asset Treasury Strategy</a>
Nuvve intends to raise additional capital to support future operational funding needs by offering up to 25% equity in Fermata 2.0.
On Monday, Nuvve launched a new wholly owned subsidiary&nbsp;that is investing in digital assets <a target="_blank" href="https://www.benzinga.com/news/25/04/45046313/nuvve-expands-beyond-evs-with-bold-bitcoin-crypto-investment-arm" rel="noreferrer noopener">and blockchain ventures</a>.
The move signals a broader shift for the company as it seeks to tap into emerging technologies beyond its focus on grid modernization and vehicle-to-grid (V2G) services.
Fermata 2.0 will be jointly led by Gregory Poilasne as CEO and Hamza Lemsaddek as Chief Operating Officer.
Immediate operational efficiencies include consolidating software platform teams and AWS infrastructure within Fermata 2.0, significantly reducing annual expenses by approximately $2 million. Sales synergies are emerging as Nuvve expands its hardware offerings into markets previously served by Fermata.
Joint engineering and R&amp;D initiatives will pursue innovation and collaborative grant-funded projects, further supported by the combined Nuvve and Fermata IP and engineering resources.
Fermata 2.0 will deliver a new generation of white-label software solutions, combining Fermata&#8217;s optimization and forecasting capabilities with Nuvve&#8217;s advanced AI-driven grid intelligence.
The assets acquisition strengthens Nuvve&#8217;s comprehensive intellectual property portfolio, diversifies market risk, and enhances its range of U.S.-built certified hardware through Fermata&#8217;s established domestic manufacturer relationships, adding resilience amid evolving tariff policies.
This assets acquisition also positions Nuvve to capitalize on accelerating regulatory tailwinds such as the Inflation Reduction Act and state-level grid modernization incentives, further expanding the total addressable market for V2G applications.
Fermata 2.0 is positioned to play a critical role in Nuvve&#8217;s growth strategy as the company expands its presence in behind-the-meter markets and strengthens its VPP services across regulated and deregulated markets alike, with the potential to drive incremental revenue from new white-label licensing opportunities, expanded DER optimization contracts, and fleet electrification partnerships.
It also provides a focused investment vehicle within Nuvve for scaling software-first energy services.
In February, Nuvve was awarded a $400 million contract from the State&nbsp;<a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/02/44051830/whats-going-on-with-nuvve-shares-friday" rel="noreferrer noopener">of New Mexico</a>.
Under the contract, Nuvve will provide a comprehensive, turnkey electrification solution over the next four years to support New Mexico&#8217;s adoption of zero-emission vehicles and renewable energy goals.
Price Action: At the last check on Tuesday, NVVE stock was trading 3% higher to $0.89 during the premarket session.

Exclusives

General

NVVE

EXCLUSIVE: Nuvve Acquires Fermata Energy, Says Deal Adds Resilience Amid Evolving Tariff Policies

SolarBank Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUUN#NASDAQ">SUUN</a>) on Tuesday announced its plans to develop a 7.2 MW DC ground-mount <a target="_blank" href="https://www.benzinga.com/topic/renewable-energy" rel="noreferrer noopener">solar power project</a> known as the Glor Rd project in upstate New York. With a secured site lease and interconnection study underway, the project is another key addition to SolarBank&#8217;s expanding development pipeline, which exceeds one gigawatt.
The project will be eligible for the VDER rate compensation mechanism under NY Public Utility Commission case 15-E-0751.
Also Read: &nbsp;<a target="_blank" href="https://www.benzinga.com/news/25/04/44947344/exclusive-solarbank-ceo-comments-on-tariffs-impact-unveils-4-584-mw-solar-project-in-new-york" rel="noreferrer noopener">SolarBank CEO Comments On Tariffs Impact, Unveils 4.584 MW Solar Project In New York</a>
The year-one average compensation is currently projected at $0.0971/kWh.
The VDER (Value of Distributed Energy Resources) rate for solar projects in New York is the rate payable to the project owner in return for the energy supplied to the grid.
Assuming the project&#8217;s interconnection study is successful, the company will continue to work to complete the permitting process and secure the necessary financing for the project&#8217;s construction.
The project will likely be eligible for incentives under the New York State Energy Research and Development Authority (&#8220;NYSERDA&#8221;) NY-Sun Program.
The company targets incentives of up to $0.245/W DC for the project. These incentives are one-time payments that help support the financing required for the project.
Once completed, the project will be operated as a community solar project. Community solar is a group of solar panels with access to the local electricity grid.
Price Action: SUUN stock traded higher by 5.43% at $2.36 premarket at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43032486/meta-boosts-green-energy-with-new-solar-deal-supporting-ai-data-center-growth" target="_blank" rel="noreferrer noopener">Meta Boosts Green Energy With New Solar Deal, Supports AI Data Center Growth</a></li>
</ul>

Market-Moving Exclusives

SUUN

EXCLUSIVE: SolarBank To Develop 7.2 MW Solar Project In New York

OSIS

OSI Systems Security Division Receives Awards Totaling $50M From Existing Customer

Milestone results formed the basis of HeartBeam's 12-lead ECG synthesis software application submitted to FDA in January 2025
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.heartbeam.com%2F&amp;esheet=54245378&amp;newsitemid=20250429345605&amp;lan=en-US&amp;anchor=HeartBeam%2C+Inc.&amp;index=1&amp;md5=c672ecafee146a571f5da284ab5c541e">HeartBeam, Inc.</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that its groundbreaking synthesized 12-lead electrocardiogram (ECG) successfully met the clinical endpoints in the VALID-ECG pivotal study. Thomas Deering, M.D., of Piedmont Heart Institute, presented the data during the just concluded Heart Rhythm Society's annual conference in San Diego.
The study evaluated the mean difference in ECG intervals and amplitudes between HeartBeam's synthesized 12-lead ECG and simultaneously collected standard 12-lead ECG that are important in assessing non-life-threatening arrhythmias. Data showed a 93.4% overall diagnostic agreement, indicating that HeartBeam's synthesized 12-lead ECG can support diagnosis of arrhythmias in a manner consistent with standard 12-lead ECGs.

BEAT

HeartBeam's Synthesized 12-lead Electrocardiogram Meets Clinical Endpoints In VALID-ECG Pivotal Study

Baird analyst Amanda Sweitzer maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and lowers the price target from $24 to $22.

Baird Maintains Outperform on Healthpeak Properties, Lowers Price Target to $22

Canaccord Genuity analyst Austin Moeller maintains Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) with a Buy and raises the price target from $15.5 to $16.

SPIR

Canaccord Genuity Maintains Buy on Spire Global, Raises Price Target to $16

TD Cowen analyst Yaron Werber downgrades SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) from Buy to Hold and lowers the price target from $66 to $47.

Downgrades

SWTX

TD Cowen Downgrades SpringWorks Therapeutics to Hold, Lowers Price Target to $47

Baird analyst Michael Ha maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Outperform and lowers the price target from $640 to $510.

Comments

Oryzon Genomics

Oryzon Genomics (ORYZF) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL